Gut microbiome effects on cardiometabolic disease through metabolism-modifying metabolites (Gut-MMM)
Research Project, 2016
– 2022
Evidence indicates that the bacterial flora in the human gastrointestinal tract substantially influences metabolism and development of cardiometabolic diseases. Nevertheless, the extent to which these factors are linked and whether pharmaceuticals can be developed on this basis are currently unclear. The underlying hypothesis of the project is that microbially synthesized molecules do not simply play a role as the body’s energy metabolizers and building blocks; they also play an important role as signal molecules that interact with receptors in endocrine organs.
Participants
Jens B Nielsen (contact)
Chalmers, Life Sciences, Systems and Synthetic Biology
Collaborations
University of Amsterdam
Amsterdam, Netherlands
University of Copenhagen
Köbenhavn, Denmark
Funding
Novo Nordisk Foundation
Project ID: NNF15OC0016798
Funding Chalmers participation during 2016–2022
Related Areas of Advance and Infrastructure
Sustainable development
Driving Forces
Life Science Engineering (2010-2018)
Areas of Advance